View study details on clinicaltrials.gov.
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
A Randomized Phase II Study Comparing Single-AgentOlaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib,Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736),Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent orMetastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent orPersistent Endometrial Cancer